17,261 trials
Postoperative Recovery
Primary: Effect of GRF6021 on Immune Responses to Surgery as Determined by Cytometry by Time of Flight (CyTOF) on Day 2 — 0.5692; 0.4521; 0.5326; 0.4471 predicted value
Allogeneic Hematopoietic Stem Cell Transplantation Recipient · Osteopenia · Osteoporosis
Primary: Mean Total Hip Percent Change in Bone Mineral Density (BMD) — -4.28 percent change
Diffuse Large B-Cell Lymphoma Unclassifiable
Primary: Overall Response Rate — 86.2 percentage of participants
Dry Eye Disease
Primary: Change From Baseline of Total Corneal Fluorescein Staining (Ora Calibra® Scale) in the Study Eye at Visit 7 (Day 29) Pre-Controlled Adverse Environment (Pre-CAE)…
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Leukemia of Ambiguous Lineage
Primary: Graft Failure — 0; 1 Participants
Metastatic Melanoma
Primary: Graded Standard Systemic Toxicities (Using CTCAE Graded Toxicity Scale) by Patient — 12 participants
Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm
Primary: Clinical Outcome in the MITT Analysis Set at EOIV. — 44; 37; 5; 12 Participants
Triple Negative Breast Cancer · Breast Cancer
Primary: Immune-based Mechanism of Action — 0.3 CD8+/Tregs ratio — p=0.101
Acute Intermittent Porphyria
Primary: Percentage of Participants With Adverse Events (AEs) — 100 percentage of participants
Influenza, Human
Primary: Percentage of Participants Reporting Local Reactions After Vaccination 1: Substudy A — 0; 0; 0; 0 Percentage of participants
GM2 Gangliosidosis · Tay-Sachs Disease · Sandhoff Disease
Primary: Clinical Impression of Change in Severity (CI-CS) [Fields et al 2021] — 0.71 score on a scale — p=0.044
Advanced or Metastatic Solid Tumors · Lung Cancer · Breast Cancer
Primary: Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 — 4; 4; 10; 12 Participants
Lupus Nephritis · Systemic Lupus Erythematosus
Primary: Phase 1b: Number of Patients Who Experienced at Least One Treatment-Related Treatment-Emergent Adverse Event — 7; 5; 11; 3 Participants
Parkinson Disease
Primary: Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "OFF" Time From Baseline to the End of Double-Blind Maintenance Period…
Breast Cancer Metastatic
Primary: Clinical Benefit Rate at 24 Weeks — 3; 18; 9 Participants